Molecular Insight Initiates Phase IIa Azedra Trial in Neuroblastoma Patients
Posted on: Friday, 2 May 2008, 09:00 CDT
Molecular Insight Pharmaceuticals has initiated a Phase IIa clinical trial of Azedra for the treatment of children with high-risk neuroblastoma, a neuroendocrine cancer that primarily affects children.
The primary objective of the trial is to determine the maximum tolerated dose (MTD) of Azedra in children with neuroblastoma. Secondary goals are to determine tumor and dose responses, determine toxicity, estimate normal organ dosimetry and describe the effect of Azedra therapy on overall quality of life. The Molecular Insight trial is being coordinated by the New Approaches to Neuroblastoma Therapy (NANT) Consortium, a group of 14 universities and Children's Hospitals with strong research and treatment programs for neuroblastoma.
Azedra is a targeted radiotherapeutic comprised of the known I-131 MIBG molecule radiolabeled using Molecular Insight's proprietary Ultratrace technology, which removes unnecessary nonradioactive molecules, or cold contaminants, to maximize therapeutic potential.
During the trial, approximately 24 patients across NANT's 14 member sites will be scanned using an imaging dose of Azedra to determine if the imaging dose demonstrates normal MIBG biodistribution and tumor uptake. Cohorts of three to six patients will then receive one therapeutic dose of Azedra within 28 days of the MIBG biodistribution and tumor uptake scan. Disease and final toxicity evaluation will be performed approximately 60 days post therapy, as will a quality of life assessment.
Source: Datamonitor
Related Articles
- Molecular Insight Pharmaceuticals, Inc. Announces Positive Results of Azedra(TM) Phase 1 Dosimetry Trial for Neuroendocrine Tumors
- Phase I Trial for ImmunoCellular Therapeutics Brain Tumor Vaccine Commences
- Pro-Pharmaceuticals Starts Dosing in Cancer Trial
- Molecular Insight Pharmaceuticals, Inc. Initiates Azedra(TM) Phase 1 Clinical Trial for Treatment of Neuroendocrine Cancer; Orphan Drug Targeted Radiotherapeutic Candidate Also Receives Fast Track Status
- First Patient Dosed in Phase 1 Trial of Tanox's TNX-650
- BioVex Begins Dosing in Melanoma Trial
- Inovio Initiates Recurrent Breast Cancer Clinical Trial Using Its Selective Electrochemical Tumor Ablation Therapy
- Current Status of Therapy of Solid Tumors
- CORRECTING AND REPLACING Study of Claims Data Finds REMICADE Dosing Remains Stable With Maintenance Therapy Over Two Year Period
- Light Therapy Helps Kill Tumors
 |
 |
User Comments (0)
RSS Feeds